Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer

Fuchs E, Schmidt L
Record ID 32018000626
Authors' objectives: Bladder cancer (urothelial carcinoma) is the sixth most common cancer worldwide. The treatment of the heterogeneous group of non-muscle invasive bladder tumours (NMIBC) with a combination of intravesical chemotherapy with regional hyperthermia (HT) -i.e. radiofrequency induced intravesical chemohyperthermia (RF-CHT)- was the subject of the systematic review of the LBI-HTA. It was investigated whether RF-CHT is safer and more effective than other interventions.
Authors' recomendations: The technology is considered experimental and should only be used in clinical trials.
Authors' methods: To evaluate the effectiveness of RF-CHT, four RCTs and one NRCT were included (503 patients, 243 of them with RF-CHT).
Project Status: Completed
Year Published: 2020
URL for published report:
URL for additional information:
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Urinary Bladder Neoplasms
  • Radiofrequency Therapy
  • Hyperthermia, Induced
  • Urothelium
  • Bladder cancer
  • urothelial carcinoma
  • oncology
  • radiofrequency therapy
  • hyperthermia
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
Contact Email:
Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.